泽布替尼治疗弥漫大B细胞淋巴瘤继发中枢神经系统浸润患者的临床疗效  

Clinical efficacy of zanubrutinib in the treatmet of diffuse large B-cell lymphoma patients with secondary central nervous system infiltration

作　　者：詹涛 曾庆芳 杨凌 ZHAN Tao;ZENG Qingfang;YANG Ling(Department of Medical Oncology,Ganzhou Cancer Hospital,Ganzhou 341000,Jiangxi,China)

机构地区：[1]赣州市肿瘤医院肿瘤内科,江西赣州3410000

出　　处：《癌症进展》2024年第20期2243-2246,共4页Oncology Progress

基　　金：江西省卫生健康委科技计划项目(202311986)。

摘　　要：目的探讨泽布替尼治疗弥漫大B细胞淋巴瘤(DLBCL)继发中枢神经系统浸润患者的临床疗效。方法根据治疗方法的不同将60例DLBCL继发中枢神经系统浸润患者分为对照组(n=28)和观察组(n=32),对照组患者采取利妥昔单抗联合氨甲蝶呤治疗,观察组患者在对照组的基础上采取泽布替尼治疗。比较两组患者的临床疗效、生活质量、不良反应发生情况及生存情况。结果观察组患者的客观缓解率、疾病控制率、生活质量好转率、2年生存率均高于对照组,不良反应总发生率低于对照组,差异均有统计学意义(P﹤0.05)。结论泽布替尼治疗DLBCL继发中枢神经系统浸润患者可提高临床疗效和生活质量,延长生存期,且具有一定的安全性。Objective To explore the clinical efficacy of zanubrutinib in the treatment of diffuse large B-cell lymphoma(DLBCL)patients with secondary central nervous system infiltration.Method According to different treatment methods,60 DLBCL patients with secondary central nervous system infiltration were divided into control group(n=28)and observation group(n=32).Patients in the control group were treated with rituximab combined with methotrexate,and patients in the observation group were treated with zanubrutinib on the basis of the control group.The clinical efficacy,quality of life,adverse reactions and survival of the two groups were compared.Result The objective response rate,disease control rate,quality of life improvement rate and 2-year survival rate of observation group were higher than those of control group,and the total incidence of adverse reactions was lower than that of control group,and the differences were statistically significant(P<0.05).Conclusion In the treatment of DLBCL patients with secondary central nervous system infiltration,zanubrutinib can improve the clinical efficacy and quality of life,prolong survival,and has a certain safety.

关 键 词：泽布替尼 弥漫大B细胞淋巴瘤 中枢神经系统浸润 临床疗效 生活质量 

分 类 号：R733.4[医药卫生—肿瘤]